Genomic medicine developer Exsilio Therapeutics has emerged from stealth with $82 million in Series A financing. The funding was co-led by Novartis Venture Fund and Delos Capital, with participation from OrbiMed, Insight Partners, JP Morgan Life Sciences Private Capital, CRISPR Therapeutics, Innovation Endeavors, Invus, Arc Ventures, and Deep Insight. Exsilio… Read More
New research has uncovered how different people respond to sepsis based on their genetics, which could lead to the development of targeted therapies. The team from the Wellcome Sanger Institute, the University of Oxford, and collaborators built on their previous work that identified different subgroups of… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. With a lead story on the restoration of congenital hearing loss following gene therapy,… Read More
News round-up for 10-14 June by DDW Senior Digital Content Editor Diana Spencer. With a lead story on the restoration of congenital hearing loss following gene therapy, the news highlights selection this week focuses on cell and gene therapies (CGT) and genetics, particularly some key progress in relation… Read More
Five children who were born with congenital hearing loss can hear in both ears after taking part in a gene therapy trial at Fudan University in Shanghai, China. Within weeks of receiving the therapy, the children could locate the sources of sounds, and recognised speech in… Read More
UK charity LifeArc has pledged £1.5 million to fund a new two-year collaborative partnership with King’s College London (KCL) to validate a portfolio of human genetic driven therapeutic targets for motor neuron disease (MND). The new partnership, which will involve scientists from both organisations working closely… Read More
Join DDW for this exclusive free event, ‘rAAV genome sequencing with Oxford Nanopore uncovers transgene integrity and packaging impurities’. The event will be supported by Oxford Nanopore Technologies. The event will feature experts Daniel Jachimowicz, Senior Bioscience Scientist at AstraZeneca BioPharmaceuticals R&D, Sweden,… Read More
Join DDW for this exclusive free event, ‘rAAV genome sequencing with Oxford Nanopore uncovers transgene integrity and packaging impurities’. The event will be supported by Oxford Nanopore Technologies. The event will feature experts Daniel Jachimowicz, Senior Bioscience Scientist at AstraZeneca BioPharmaceuticals R&D, Sweden,… Read More
Join DDW for this exclusive free event, ‘rAAV genome sequencing with Oxford Nanopore uncovers transgene integrity and packaging impurities’. The event will be supported by Oxford Nanopore Technologies. The event will feature experts Daniel Jachimowicz, Senior Bioscience Scientist at AstraZeneca BioPharmaceuticals R&D, Sweden,… Read More
Join DDW for this exclusive free event, ‘rAAV genome sequencing with Oxford Nanopore uncovers transgene integrity and packaging impurities’. The event will be supported by Oxford Nanopore Technologies. The event will feature experts Daniel Jachimowicz, Senior Bioscience Scientist at AstraZeneca BioPharmaceuticals R&D, Sweden,… Read More
Join DDW for this free event, ‘CRISPR screening at scale: Achieving 1M cell data sets with an instrument-free, cost-effective approach‘, which is supported by Scale Biosciences. The event will take place on 25 April 5 PM BST / 6PM CEST / 9AM PST. Read More
Recombinant adeno-associated viruses (rAAVs) are considered a promising delivery system for gene therapy medicines. This webinar highlights how long-read nanopore sequencing as a comprehensive and sensitive QC method for rAAVs were evaluated — which is supporting internal research activities at AstraZeneca. You will hear how library preparation, assessed data quality,… Read More
Join DDW for this free event, ‘CRISPR screening at scale: Achieving 1M cell data sets with an instrument-free, cost-effective approach‘, which is supported by Scale Biosciences. The event will take place on 25 April 5 PM BST / 6PM CEST / 9AM PST. Read More
Join DDW for this free event, ‘CRISPR screening at scale: Achieving 1M cell data sets with an instrument-free, cost-effective approach‘, which is supported by Scale Biosciences. The event will take place on 25 April 5 PM BST / 6PM CEST / 9AM PST. Read More
Join DDW for this free event, ‘CRISPR screening at scale: Achieving 1M cell data sets with an instrument-free, cost-effective approach‘, which is supported by Scale Biosciences. The event will take place on 25 April 5 PM BST / 6PM CEST / 9AM PST. Read More
Pooled CRISPR screens offer the ability to knock out or perturb many genes in a single experiment from several hundred to tens of thousands of targets in parallel. Genome-wide screens are becoming the standard for drug discovery to power unbiased identification of drug targets across gene regulatory networks. Requiring single-cell… Read More
